Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 54,972 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Clear all
Completed Phase 4 Interventional

CATIE- Schizophrenia Trial

NCT00014001
View directory record Official record
Conditions
Schizophrenia
Interventions
perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
54
States / cities
Chula Vista, California • Los Angeles, California • Orange, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Nov 11, 2026, 5:59 PM EST
Terminated Not applicable Interventional

Selenium Supplementation of Patients With Cirrhosis

NCT00212212
View directory record Official record
Conditions
Cirrhosis
Interventions
selenium, placebo
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 1 Interventional

Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT00415324
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
eribulin mesylate, cisplatin, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Nov 11, 2026, 5:59 PM EST
Terminated Phase 2 Interventional

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

NCT00048659
View directory record Official record
Conditions
Hormone-Refractory Prostate Cancer, Prostatic Neoplasms
Interventions
YM598
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Anchorage, Alaska • San Bernardino, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Nov 11, 2026, 5:59 PM EST
Completed Not applicable Interventional Results available

Patient Anxiety Associated With Lymphedema Surveillance Method

NCT02033759
View directory record Official record
Conditions
Anxiety
Interventions
Bio-Impedance Testing, Anxiety Questionnaire, Traditional Circumferential Measurements
Device · Other
Lead sponsor
Mercy Research
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 2 Interventional Results available

Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

NCT01175980
View directory record Official record
Conditions
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage III Major Salivary Gland Cancer AJCC v7, Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Tongue Carcinoma
Interventions
Laboratory Biomarker Analysis, Vorinostat
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
11
States / cities
Duarte, California • South Pasadena, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 4 Interventional Results available

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

NCT00977080
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
Interventions
Paricalcitol, Cinacalcet
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 2 Interventional Results available

Study Comparing Two Types of Ports in Patients With Cancer Receiving Intravenous Chemotherapy

NCT00607880
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Vascular Access Device Complications
Interventions
vascular access device placement
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Nov 11, 2026, 5:59 PM EST
Not yet recruiting Phase 2 Interventional

Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients

NCT07891780
View directory record Official record
Conditions
Epinephrine, Hypersensitivity, Immediate, Anaphylaxis
Interventions
Epinephrine Nasal Spray, 2.5 mg, Epinephrine Nasal Spray, 5.25 mg
Drug
Lead sponsor
Hikma Pharmaceuticals USA Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 2 Interventional Results available

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

NCT00952380
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
dalteparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Up to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
17
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Nov 11, 2026, 5:59 PM EST
Completed No phase listed Observational

Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

NCT05576779
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ofatunumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 2 Interventional

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

NCT00050596
View directory record Official record
Conditions
Prostate Cancer
Interventions
MDX-010 / MDX-010 + Docetaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Tucson, Arizona • Long Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Nov 11, 2026, 5:59 PM EST
Not listed Phase 3 Interventional

Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS

NCT02415803
View directory record Official record
Conditions
Non ST Segment Elevation Acute Coronary Syndrome
Interventions
low-dose ticagrelor, conventional-dose ticagrelor, Clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Nov 11, 2026, 5:59 PM EST
Terminated Phase 2 Interventional Results available

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

NCT04404361
View directory record Official record
Conditions
COVID19, COVID-19, COVID
Interventions
Pacritinib, Placebo
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Orange, California • Jacksonville, Florida • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Nov 11, 2026, 5:59 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01832727
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Oprozomib, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Westwood, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 2 Interventional

Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

NCT00303927
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
capecitabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2010 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

NCT00003761
View directory record Official record
Conditions
Breast Cancer
Interventions
rV-DF3/MUC1
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger

NCT00348478
View directory record Official record
Conditions
Trachoma
Interventions
water and health education program to improve hygiene
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Months to 65 Months
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2011 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 2 Interventional

Repinotan in Patients With Acute Ischemic Stroke

NCT00044915
View directory record Official record
Conditions
Stroke, Acute Ischemic Stroke
Interventions
Repinotan HCl (BAYX3702), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
28
States / cities
Los Angeles, California • Oceanside, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Nov 11, 2026, 5:59 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies

NCT05950308
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Nov 11, 2026, 5:59 PM EST
Completed Phase 3 Interventional

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

NCT00649025
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
21
States / cities
Scottsdale, Arizona • Tempe, Arizona • Encinitas, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Nov 11, 2026, 5:59 PM EST
Completed Not applicable Interventional Results available

Motivational Interviewing to Enhance Adherence of Patients With Psychogenic Non-epileptic Seizures

NCT02598076
View directory record Official record
Conditions
Psychogenic Non-epileptic Seizures, Motivational Interviewing
Interventions
motivational interviewing, standard psychotherapy
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Nov 11, 2026, 5:59 PM EST
Withdrawn Not applicable Interventional

Welcoming by Design Pilot: Reducing Structural Stigma by Changing Clinic Systems and Architectural Design

NCT05642676
View directory record Official record
Conditions
Hiv
Interventions
Clinics remodeling
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Nov 11, 2026, 5:59 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

NCT03287817
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
AUTO3
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Duarte, California • Denver, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Nov 11, 2026, 5:59 PM EST